Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Shock. 2014 Nov;42(5):424–431. doi: 10.1097/SHK.0000000000000231

Figure 4.

Figure 4

Erythropoietin (rhEPO) treatment decreases apoptosis after liver ischemia-reperfusion (IR). A, B. Immunohistochemistry for activated caspase 3 in untreated liver after IR demonstrates immunoreactivity in non-parenchymal cells. B. rhEPO treatment prevents caspase activation after IR, as shown by immunohistochemistry. C. A fluorogenic caspase activity assay performed after IR shows that rhEPO decreases caspase activity in the ischemic liver. * = p<0.05 in treated vs. untreated samples